

# Robert J Slack

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4489378/publications.pdf>

Version: 2024-02-01

9  
papers

338  
citations

1307594  
7  
h-index

1474206  
9  
g-index

9  
all docs

9  
docs citations

9  
times ranked

510  
citing authors

#	ARTICLE	IF	CITATIONS
1	An $\alpha$ 5 $\beta$ 1 Integrin Inhibitor Toolbox: Drug Discovery Insight, Challenges and Opportunities. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 3298-3321.	13.8	94
2	Translational pharmacology of an inhaled small molecule $\alpha$ 5 $\beta$ 1 integrin inhibitor for idiopathic pulmonary fibrosis. <i>Nature Communications</i> , 2020, 11, 4659.	12.8	65
3	Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin $\alpha$ 5 $\beta$ 1 inhibitor, in healthy participants. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 701-709.	1.9	52
4	A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled $\alpha$ 5 $\beta$ 1 integrin inhibitor. <i>Respiratory Research</i> , 2020, 21, 75.	3.6	41
5	Discovery of (S)-3-(3-(3,5-Dimethyl-1H-pyrazol-1-yl)phenyl)-4-((R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)propanoic Acid, a Nonpeptidic $\alpha$ 5 $\beta$ 1 Integrin Inhibitor for the Inhaled Treatment of Idiopathic Pulmonary Fibrosis. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8417-8443.	6.4	31
6	Pharmacological Characterization of the $\alpha$ 5 $\beta$ 1 Integrin Binding and Internalization Kinetics of the Foot-and-Mouth Disease Virus Derived Peptide A20FMDV2. <i>Pharmacology</i> , 2016, 97, 114-125.	2.2	26
7	Characterisation of a novel, high affinity and selective $\alpha$ 5 $\beta$ 1 integrin RGD-mimetic radioligand. <i>Biochemical Pharmacology</i> , 2016, 117, 88-96.	4.4	23
8	Downregulation of the $\alpha$ 5 $\beta$ 1 Integrin via RGD Engagement Is Affinity and Time Dependent. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 376, 273-280.	2.5	3
9	Pharmacological characterisation of GSK3335103, an oral $\alpha$ 5 $\beta$ 1 integrin small molecule RGD-mimetic inhibitor for the treatment of fibrotic disease. <i>European Journal of Pharmacology</i> , 2021, 913, 174618.	3.5	3